论文部分内容阅读
目的:评估妊娠晚期使用乙型肝炎免疫球蛋白(hepatitisBimmunoglobulin,HBIG)阻断乙型肝炎病毒(hepatitisBvirus,HBV)宫内感染的疗效。方法:112例血清HBsAg阳性孕妇随机分为两组:HBIG组57例,于孕28周起肌内注射HBIG,200U,每4周1次,至分娩;对照组55例,未予用药。两组孕妇均于孕28周和分娩前,其新生儿于出生时检测外周血乙型肝炎病毒脱氧核糖核酸(hepatitisBvirusdeoxyribonucleicacid,HBVDNA)水平及肝炎血清标志物。结果:HBIG组和对照组宫内感染率分别为11%和27%,差异有统计学意义(P<0.05)。宫内感染率随孕晚期母血HBVDNA含量增加呈增高趋势。结论:孕妇产前多次注射HBIG可有效降低HBV宫内感染率,母血HBVDNA等于或超过108拷贝/毫升者宫内感染可能性增大。
Objective: To evaluate the efficacy of hepatitis B immunoglobulin (HBIG) in blocking the intrauterine infection of hepatitis B virus (HBV) in the third trimester of pregnancy. Methods: One hundred and twelve cases of HBsAg positive pregnant women were randomly divided into two groups: 57 cases of HBIG group, intramuscular injection of HBIG at 28 weeks’ gestation, 200U once every 4 weeks until delivery; control group, 55 cases without medication. Both groups of pregnant women were tested for HBV DNA level and serum hepatitis B markers in their peripheral blood at 28 weeks’ gestation and before delivery. Results: The intrauterine infection rates in HBIG group and control group were 11% and 27%, respectively, with statistical significance (P <0.05). The intrauterine infection rate increased with the increase of HBVDNA content in the third trimester of pregnancy. Conclusion: Multiple prenatal injections of HBIG in pregnant women can effectively reduce the intrauterine infection rate of HBV, and the possibility of intrauterine infection of maternal HBVDNA equal to or exceeding 108 copies / ml increases.